July 2019
Volume 60, Issue 9
Open Access
ARVO Annual Meeting Abstract  |   July 2019
Insulin-like growth factor 1 receptor (IGF-1R) expression in peripheral blood mononuclear cells (PBMC) in Thyroid-Associated Orbitopathy (TAO)
Author Affiliations & Notes
  • Kam-lung, Kelvin Chong
    Ophthalmology and Visual Science, The Chinese University of Hong Kong, Hong Kong, Hong Kong
  • WAI KIT CHU
    Ophthalmology and Visual Science, The Chinese University of Hong Kong, Hong Kong, Hong Kong
  • Footnotes
    Commercial Relationships   Kam-lung, Kelvin Chong, None; WAI KIT CHU, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science July 2019, Vol.60, 6205. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Kam-lung, Kelvin Chong, WAI KIT CHU; Insulin-like growth factor 1 receptor (IGF-1R) expression in peripheral blood mononuclear cells (PBMC) in Thyroid-Associated Orbitopathy (TAO). Invest. Ophthalmol. Vis. Sci. 2019;60(9):6205.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : IGF-1 receptor (IGF-1R) pathway was shown to be involved at critical processes pertaining to the pathogenesis of Thyroid-Associated Orbitopathy (TAO) and the recent breakthrough in a double-masked, randomized controlled trial using humanized monoclonal antibody inhibitor of IGF-IR (teprotumumab) in patients with active TAO further reinforced its roles. We hypothesize that IGF-1R positive PBMC exit circulation and infiltrate to the orbital tissues. We prospectively compared the level of expression of IGF-1R in peripheral blood mononuclear cells (PBMC) in patients with progressive Thyroid-Associated Orbitopathy (TAO) before any immunosuppressive treatment and those with only Graves Disease (GD) but no clinically evident TAO.

Methods : Euthyroid patients who were referred for recent-onset (<9-month), progressive TAO (n=20) as well as those with GD only (n=20) were recruited. The presence of orbitopathy and disease activity were evaluated by a single oculoplastic surgeon. PBMC were prepared from venous blood, isolated by red cell lysis, fixed and stained by masked laboratory personnel while isotype control was prepared by staining with secondary antibody only. IGF-1R expressions were measured using flow cytometry (FACS Calibur, BD Biosciences). Percentage of IGF-1R positive expression was determined as the population of gated viable cells with increased fluorescent intensity compared with those in isotype control.

Results : Age, gender, smoking and family history, use of antithyroid medication, thyroxine supplement or radioactive iodide, duration of GD as well as the most recent thyroid function were not significantly different between groups (all p>0.5). Patients with GD alone show significantly more circulating IGF1R positive PBMC than patients with TAO (99+/-4% vs 65+/-5%, p < 0.01, Mann-Whitney test).

Conclusions : Percentage of IGF-1R positive PBMC was found to be lower in patients with recent-onset TAO compared to those with GD only. Serially monitoring of IGF-1R expression in PBMC may be a surrogate biomarker to identify GD patients at risk of developing progressive TAO.

This abstract was presented at the 2019 ARVO Annual Meeting, held in Vancouver, Canada, April 28 - May 2, 2019.

 

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×